Under way, not recruiting
Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer
NCT05918783 · Impact Biotech Ltd · Updated 8 Oct 2026
- What is being tested
- Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
- For
- Peripheral Lung Tumor
- Kind of study
- Tests a treatment or device on volunteers. Phase 1.
- Who can join
- Ages 18 years and older. About 36 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 28 May 2024, ends 30 Dec 2028. Registered 26 June 2023.
- Results
- None posted yet.
In the researchers' words
Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects. Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days following the VTP procedure. Study intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer.
Sites
- Johns Hopkins University School of MedicineBaltimore, Maryland, United States